Business Context and Reporting Period
This Form 8-K is filed by Zafgen, Inc. (not Larimar Therapeutics, Inc.) on November 9, 2016. The report announces the company's financial results for the third quarter of 2016. The filing incorporates a press release (Exhibit 99.1) by reference but does not contain the detailed financial tables within the text of the 8-K itself.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. These specific metrics are contained within the referenced press release (Exhibit 99.1) which is not included in the provided input text.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this Form 8-K. The document serves solely as a notification that third-quarter results have been announced.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities of that section. No specific guidance, outlook, management commentary, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name is Zafgen, Inc., as the input metadata incorrectly listed Larimar Therapeutics, Inc.
- Locate and review Exhibit 99.1 (the press release) to obtain actual Q3 2016 financial figures.
- Confirm the filing date of November 9, 2016, aligns with the company's standard reporting calendar.
- Note that this 8-K is a notification of results, not a comprehensive financial statement.